INCHEON, South Korea and JERSEY CITY, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Organon & Co. (NYSE: OGN) today announced that the U.S. Food and Drug Administration (FDA) ...
The approval of the interchangeable designation was supported by data from a randomized, double-blind phase 4 trial (ClinicalTrials.gov Identifier: NCT05510063) that assessed the pharmacokinetics, ...
Autoinjector recognized by the Arthritis Foundation with Ease of Use Certification Individualized patient support program “HADLIMA For You” available including co-pay support Designed to improve ...
Samsung Bioepis and Organon shared that the Food and Drug Administration has designated the Hadlima (adalimumab-bwwd) high- and low-concentration (40 mg/0.4 ml, 40 mg/0.8 ml) autoinjectors and ...
Share on Pinterest Humira will soon have a citrate-free biosimilar available on the market. Humira (adalimumab) is a popular medication used to treat various inflammatory conditions including ...
(Reuters) - Drugmaker partners Organon and Samsung Bioepis said on Saturday that they had launched a far cheaper copycat version of AbbVie’s blockbuster arthritis drug Humira, while two other ...
As widely expected by the pharmaceutical industry, seven pharmaceutical companies are releasing biosimilars of AbbVie's Humira. Boehringer Ingelheim's Cyltezo (adalimumab-adbm), an interchangeable ...
Autoinjector recognized by the Arthritis Foundation with Ease of Use Certification Individualized patient support program “HADLIMA For You” available including co-pay support Designed to improve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results